Boston Scientific accounts are for healthcare professionals only.
EluPro™ Antibiotic-Eluting BioEnvelope
Reimbursement
Configure or select a product to continue to order
- Overview
- Implant Technique
- Ordering information
- Resources
EluPro Antibiotic-Eluting BioEnvelope
EluPro BioEnvelope provides localized antibiotic protection, supports natural healing, and contributes to a more manageable pocket over time for safer, more stable cardiac implants.1
How it works
EluPro pairs local antibiotic delivery with regenerative extra cellular matrix (ECM) technology in an innovative approach to CIED pocket healing. The bioenvelope delivers the trusted antibiotics rifampin and minocycline directly at the implant site, providing broad-spectrum protection against pathogens linked to CIED infections.2,3 The antibiotics elute locally over at least seven days,3 helping maintain effective levels during the period of highest infection risk without increasing systemic antibiotic exposure.¹
By combining antimicrobial defense with a biologic scaffold, EluPro helps create a more physiologic implant environment, supports healthy tissue regrowth, and reduces pocket fibrosis, migration, and erosion.1,3-4 The bioenvelope is designed to make long-term pocket management more predictable by mitigating complications associated with scar formation.1,3
Why choose the EluPro BioEnvelope?
EluPro combines proven infection protection with regenerative healing in one bioenvelope, helping reduce post-implant complications while supporting healthy, vascularized tissue growth.
100% bacterial kill in preclinical testing
Successfully eliminated bacterial colonization, thus reducing the potential for infection.3,5
Soft feel and natural lubricity
Conforms to the shape of the CIED to enhance the implantation experience with no modification necessary to the envelope or incision.1,6
Supports natural biologic healing
Reduces foreign-body response, which mitigates inflammation and fosters vascularization and integration.1,7
The EluPro Antibiotic-Eluting BioEnvelope has earned Vizient’s Innovative Technology designation. This designation recognizes technologies that demonstrate innovation and the potential to make a meaningful difference in clinical and economic outcomes.
Key features and specifications
Localized antibiotic protection
EluPro delivers rifampin and minocycline directly at the implant site, providing broad-spectrum antimicrobial protection against pathogens most often associated with CIED infections.2,3 The antibiotics elute gradually for at least seven days3, maintaining effective levels during the period of highest infection risk.
Biologic matrix for natural healing
Constructed from a biocompatible, biologic material, the EluPro BioEnvelope supports natural tissue remodeling and vascularization.6-9 This regenerative scaffold minimizes inflammation and foreign-body response, helping create a stable implant pocket with healthy tissue.
Enhanced surgical handling
The soft, conformable biomatrix easily adapts to various CIED shapes and sizes. Its natural lubricity supports device placement, pocket closure, and procedural efficiency while maintaining structural integrity during handling.1,6
Reduced reoperation complexity
In clinical studies, the bioenvelope technology has been shown to decrease lead adhesions and simplify reoperative procedures.7-9 The result is easier device replacement and less disruption to surrounding tissue.
Extended local efficacy without systemic impact
By concentrating antibiotic activity at the surgical site, EluPro reduces reliance on systemic antibiotic dosing.3 This targeted approach may provide high local efficacy while limiting systemic exposure and potential antibiotic resistance concerns.
EluPro is MR Safe. MR Safe items pose no safety hazards in the MR environment. They may be placed anywhere in the MR environment. Patients with MR Safe devices have no scanning restrictions.
Implant technique
EluPro offers a quick, easy implant technique that fits your workflow.
Step 1:
To use, select the appropriate size EluPro for the CIED. Handle the sterile bioenvelope using aseptic technique.
Step 2:
Hydrate EluPro by immersing it completely in sterile solution (e.g. saline, water) for 1-2 minutes.
Step 3:
Slide the CIED into EluPro, with lead wires emerging out of the opening. Secure the bioenvelope with one stitch.
Step 4:
Implant the CIED with the bioenvelope into the pocket and secure it to the fascia per standard practice.
Ordering information
| Description | Model | Specs | Quantity |
| EluPro BioEnvelope Size 2 | BE02 | 6.9cm x 6.5cm | Single pack |
| EluPro BioEnvelope Size 3 | BE03 | 6.9cm x 8.0cm | Single pack |
EluPro BioEnvelope size 2 BE02
EluPro BioEnvelope size 3 BE03
Product resources
The EluPro difference
Antibiotic protection is only part of the pocket management story. EluPro pairs localized antibiotic delivery with regenerative extracellular matrix (ECM) technology to support healing and long-term pocket health.
Brochure
Videos
Optimizing the device pocket: My experience with the EluPro Antibiotic-Eluting BioEnvelope
Dr. Jonathan Weinstock FACC, FHRS and Dr. Sunil Kapur explore the challenges of CIED pocket healing, the importance of long-term pocket health, and how EluPro leverages extra cellular matrix technology to support a biologic approach to tissue remodeling.
Subscribe for updates on EluPro
Receive timely updates on significant announcements, exclusive opportunities to engage with peers through educational events, and access valuable tools to enhance your ability to assist more patients.
Related products
References:
- Catanzaro JN, et al. Preclinical and clinical evaluation of ECM bioenvelopes for preventing CIED pocket complications. Front Cardiovasc Med. 2025;12:1638929. doi:10.3389/fcvm.2025.1638929
- Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49(18):1851-1859. doi:10.1016/j.jacc.2007.01.072
- Garrigos ZE, Catanzaro JN, Deegan D, Zhang J, Sohail MR. Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention. Front Drug Deliv. 2024;4:1441956. doi:10.3389/fddev.2024.1441956
- Haney LC, et al. More than 400 uses of an intestinal submucosal extracellular matrix patch in a congenital heartprogram. Ann ThoracSurg. 2022;114(4):1475-1483. doi:10.1016/j.athoracsur.2021.06.087
- Büttner H, Kramer A, Fux M, et al. Bacterial colonization and infection prevention in implantable devices: insights from preclinical models. Front Cell Infect Microbiol. 2015;5:14.
- Catanzaro JN, Wood MM, Kramer KB, et al. Clinical outcomes of bioenvelope use during CIED changeouts: the HEAL study. Heart Rhythm. 2023;20(5 suppl):S712-S713.
- Deegan D, Piasecki SK, Riebman JB. An acellular biologic extracellular matrix envelope for cardiovascular implantable electronic devices: preclinical evaluation. J Regen Med. 2022;11(5):Article 5. doi:10.1097/01.mat.0000841052.84245.36
- Srivastava A, Nayak HM. Regenerative response following CIED reimplantation with a biologic envelope. HeartRhythm Case Rep. 2023;9(12):797-799.
- Catanzaro JN, Wood MM, Kramer KB, et al. Comparative tissue response with biologic vs non-biologic device envelopes. Circulation. 2022;146(suppl 1):A11052.